Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Assessing the toxicity and associated costs among pediatric patients admitted with unintentional poisonings of attention-deficit/hyperactivity disorder drugs in the United States.

Levine M, Froberg B, Ruha AM, Burns-Ewald M, Yen M, Claudius IA, Arthur AO, Tormoehlen L, Thomas SH.

Clin Toxicol (Phila). 2013 Mar;51(3):147-50. doi: 10.3109/15563650.2013.772623.

PMID:
23473458
2.

Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.

Aldridge AP, Kroutil LA, Cowell AJ, Reeves DB, Van Brunt DL.

Pharmacoeconomics. 2011 Jul;29(7):621-35. doi: 10.2165/11584590-000000000-00000.

PMID:
21473655
3.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.

PMID:
18042808
4.

Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.

Leibson CL, Barbaresi WJ, Ransom J, Colligan RC, Kemner J, Weaver AL, Katusic SK.

Ambul Pediatr. 2006 Jan-Feb;6(1):45-53.

PMID:
16443183
5.
6.

Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.

Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ.

J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990-1002.e2. doi: 10.1016/j.jaac.2012.07.008. Epub 2012 Sep 5. Review.

PMID:
23021476
7.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.

Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

CNS Drugs. 2012 Jul 1;26(7):581-600. doi: 10.2165/11633900-000000000-00000. Review.

PMID:
22712698
8.

ADHD medication use, adherence, persistence and cost among Texas Medicaid children.

Barner JC, Khoza S, Oladapo A.

Curr Med Res Opin. 2011;27 Suppl 2:13-22. doi: 10.1185/03007995.2011.603303.

PMID:
21973228
9.

Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national population-based study.

Chien IC, Lin CH, Chou YJ, Chou P.

Soc Psychiatry Psychiatr Epidemiol. 2012 Dec;47(12):1885-90. doi: 10.1007/s00127-012-0501-1. Epub 2012 Apr 4.

PMID:
22476209
10.

Kawasaki syndrome hospitalizations and associated costs in the United States.

Belay ED, Holman RC, Maddox RA, Foster DA, Schonberger LB.

Public Health Rep. 2003 Sep-Oct;118(5):464-9.

11.

National estimates of the inpatient burden of pediatric bipolar disorder in the United States.

Berry EA, Heaton PT, Kelton CM.

J Ment Health Policy Econ. 2011 Sep;14(3):115-23.

PMID:
22116169
12.

Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.

Power TJ, Mautone JA, Manz PH, Frye L, Blum NJ.

Pediatrics. 2008 Jan;121(1):e65-72. doi: 10.1542/peds.2007-0383.

PMID:
18166546
13.

Comparison of prescription drug costs in the United States and the United Kingdom, part 3: methylphenidate.

Jick H, Wilson A, Wiggins P, Chamberlin DP.

Pharmacotherapy. 2012 Nov;32(11):970-3. doi: 10.1002/phar.1141. Epub 2012 Oct 26.

PMID:
23108719
14.
15.

Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.

Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Escudero A, Velasco A, Carvajal A.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):435-41. doi: 10.1002/pds.2348. Epub 2012 Jan 17.

PMID:
22253017
16.

Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.

Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR.

Curr Med Res Opin. 2005 Feb;21(2):195-206.

PMID:
15801990
17.

Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.

Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA.

Arch Pediatr Adolesc Med. 1999 Dec;153(12):1257-63.

PMID:
10591302
18.

Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children --- United States, 2003 and 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Nov 12;59(44):1439-43.

19.

Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications.

Bruckner TA, Hodgson A, Mahoney CB, Fulton BD, Levine P, Scheffler RM.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):442-9. doi: 10.1002/pds.2264. Epub 2011 Oct 24.

PMID:
22021031
20.

Second opinions improve ADHD prescribing in a medicaid-insured community population.

Thompson JN, Varley CK, McClellan J, Hilt R, Lee T, Kwan AC, Lee T, Trupin E.

J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):740-8. doi: 10.1097/CHI.0b013e3181a2b2ed.

PMID:
19465882
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk